It has been shown that glioma cells overexpressing galectin-1 are capable to evade NK immune surveillance, whereas the lack of galectin-1 leads to accentuated tumor-killing effects of NK cells by releasing granzyme B [50, 77]. The gene discussed is GZMB; the disease is central nervous system cancer.